CD20 Antibody (B-Ly1) [Allophycocyanin]

Flow Cytometry: CD20 Antibody (B-Ly1) [Allophycocyanin] [NBP1-28384] - Human peripheral blood lymphocytes were stained with Mouse Anti-Human CD20-APC and Mouse Anti-Human CD19-FITC.

• Reactivity: Hu
• Applications: Flow
• Clone: B-Ly1
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Allophycocyanin

CD20 Antibody (B-Ly1) [Allophycocyanin] Summary

• Additional Information: Clone B-Ly1 was used by HLDA to establish CD designation.
• Immunogen: The immunogen is a peptide made to the amino acid region CD20
• Specificity: Human CD20
• Isotype: IgG1 Kappa
• Clonality: Monoclonal
• Host: Mouse
• Gene: MS4A1
• Purity: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 10 uL/10^6 cells

Reactivity Notes

Feline reactivity reported from a verified customer review.

Packaging, Storage & Formulations

• Storage: Store at 4C. Do not freeze.
• Buffer: PBS and a stabilizing agent
• Preservative: 0.1% Sodium Azide
• Purity: Protein A or G purified

Notes

Protect conjugated forms from light.

Alternate Names for CD20 Antibody (B-Ly1) [Allophycocyanin]

• B1
• B-lymphocyte antigen CD20
• B-lymphocyte cell-surface antigen B1
• B-lymphocyte surface antigen B1
• Bp35
• Bp35MGC3969
• CD20 antigen
• CD20 receptor
• CD20
• CD20S7
• CVID5
• LEU-16
• Leukocyte surface antigen Leu-16
• Ly-44
• Membrane-spanning 4-domains subfamily A member 1
• membrane-spanning 4-domains, subfamily A, member 1
• MS4A1
• MS4A2
• S7

Background

CD20 is a non-glycosylated phosphoprotein that is expressed on the surface of normal and malignant B cells and functions in mediating calcium transport and B cell differentiation (1,2). CD20 is encoded by the membrane-spanning 4-domain family A member 1 (MS4A1) gene and, in humans, is located on chromosome 11q12 (1). The CD20 protein is 297 amino acids (aa) in length with a theoretical molecular weight (MW) of 33 kDa (1,2). Structurally, the CD20 protein has four membrane-spanning domains, two extracellular loop domains, and intracellular N- and C-terminal domains (1,2). CD20 is expressed at specific stages of B cell maturation including pre-B cells, mature naive and activated B cells, and memory B cells, but is absent from plasmablasts and plasma cells (1,3,4). Expression of CD20 is often increased on malignant B cells associated with various B cell disorders such as chronic lymphocytic leukemia (CLL), multiple sclerosis (MS), and rheumatoid arthritis (2-4). Anti-CD20 monoclonal antibody (mAb)-based therapies have become an appealing target for treating these immune-related disorders and cancers (1-5). Rituximab, a chimeric mAb, was the first FDA approved CD20 monoclonal antibody for the treatment of non-Hodgkin's lymphoma that is now commonly used to treat MS (2,3). Since its initial approval in 1997, several other chimeric and humanized anti-CD20 mAbs have been developed including Ofatumumab, Ublituximab, and Obinutuzumab (1-5). B cell depletion via CD20 mAbs can occur under different mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis (1-4). Many ongoing studies are focused on combination therapies with CD20 mAbs as an addition to chemotherapy, B cell receptor (BCR) signaling inhibitors, or BH3 mimetics (1,2,4). Additionally, the effects of bispecific antibodies and CD20 chimeric antigen receptor (CAR) T cell therapies are under investigation for the treatment of B cell malignancies (4,5).

References

1. Pavlasova G, Mraz M. The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy. Haematologica. 2020; 105(6):1494-1506. https://doi.org/10.3324/haematol.2019.243543

2. Payandeh Z, Bahrami AA, Hoseinpoor R, et al. The applications of anti-CD20 antibodies to treat various B cells disorders. Biomed Pharmacother. 2019; 109:2415-2426. https://doi.org/10.1016/j.biopha.2018.11.121

3. Margoni M, Preziosa P, Filippi M, Rocca MA. Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. J Neurol. 2022; 269(3):1316-1334. https://doi.org/10.1007/s00415-021-10744-x

4. Klein C, Jamois C, Nielsen T. Anti-CD20 treatment for B-cell malignancies: current status and future directions. Expert Opin Biol Ther. 2021; 21(2):161-181. https://doi.org/10.1080/14712598.2020.1822318

5. Sharman JP. Targeting CD20: teaching an old dog new tricks. Hematology Am Soc Hematol Educ Program. 2019; 2019(1):273-278. https://doi.org/10.1182/hematology.2019000031

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Review for CD20 Antibody (NBP1-28384) (1)

Average Rating: 5

(Based on 1 review)

We have 1 review tested in 1 species: Feline.

reviewed by: Verified Customer Flow Feline 10/23/2017

Summary

• Application: Flow Cytometry
• Sample Tested: Whole blood cells
• Species: Feline
• Lot: VJ20T

Bioinformatics

• Gene Symbol: MS4A1